Clinical PD-1/PD-L1 Blockades in Combination Therapies for Lymphomas

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Nov 25

PMID 38001659

Authors

Hiroo Katsuya

Junji Suzumiya

Shinya Kimura

Affiliations

Soon will be listed here.

Abstract

Immunotherapy with the programmed cell death protein 1 (PD-1)/PD-1 ligand (PD-L1) blockade has revolutionized the treatment of advanced solid cancers. However, these clinical benefits have been limited to cases of malignant lymphomas, showing promising results for only classic Hodgkin lymphoma (cHL) and primary mediastinal B-cell lymphoma (PMBCL). To bring clinical benefits to more patients with lymphoma, numerous combination therapies involving PD-1/PD-L1 blockade have been tested in clinical trials in both frontline and relapsed/refractory settings. This article reviews the current landscape of combination therapies with PD-1/PD-L1 blockade for lymphoma and discusses the potential therapeutic approaches. An interim analysis of a phase 3 study demonstrated increased progression-free survival with nivolumab combination therapy over the current frontline treatment in patients with advanced-stage cHL. The results of combination therapies for aggressive B-cell lymphomas, except for PMBCL, have been disappointing. Several clinical trials of combined PD-1/PD-L1 blockade and Bruton's tyrosine kinase inhibitors are exploring its efficacy in patients with chronic lymphocytic leukemia (CLL) with Richter transformation. Several T-cell lymphoma subtypes respond to PD-1/PD-L1 blockade monotherapy. Further clinical trials are underway to investigate appropriate combination regimens with PD-1/PD-L1 blockade, especially for cHL, CLL with Richter transformation, and T-cell lymphoma, in both frontline and relapsed/refractory settings.

Citing Articles

Shedding Light on the Role of Exosomal PD-L1 (ExoPD-L1) in Cancer Progression: an Update.

Sun D, Altalbawy F, Yumashev A, Hjazi A, Menon S, Kaur M Cell Biochem Biophys. 2024; 82(3):1709-1720.

PMID: 38907940 DOI: 10.1007/s12013-024-01340-7.

References

Alaggio R, Amador C, Anagnostopoulos I, Attygalle A, de Oliveira Araujo I, Berti E . The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36(7):1720-1748. PMC: 9214472. DOI: 10.1038/s41375-022-01620-2. View

Twa D, Chan F, Ben-Neriah S, Woolcock B, Mottok A, Tan K . Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood. 2014; 123(13):2062-5. DOI: 10.1182/blood-2013-10-535443. View

Grommes C, Pastore A, Palaskas N, Tang S, Campos C, Schartz D . Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. Cancer Discov. 2017; 7(9):1018-1029. PMC: 5581705. DOI: 10.1158/2159-8290.CD-17-0613. View

Brockelmann P, Buhnen I, Meissner J, Trautmann-Grill K, Herhaus P, Halbsguth T . Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial. J Clin Oncol. 2022; 41(6):1193-1199. DOI: 10.1200/JCO.22.02355. View

Khodadoust M, Rook A, Porcu P, Foss F, Moskowitz A, Shustov A . Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study. J Clin Oncol. 2019; 38(1):20-28. PMC: 6943974. DOI: 10.1200/JCO.19.01056. View

Palomba M, Till B, Park S, Morschhauser F, Cartron G, Marks R . Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Results from a Phase 1b Study. Clin Lymphoma Myeloma Leuk. 2022; 22(7):e443-e451. DOI: 10.1016/j.clml.2021.12.010. View

Roemer M, Advani R, Ligon A, Natkunam Y, Redd R, Homer H . PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. J Clin Oncol. 2016; 34(23):2690-7. PMC: 5019753. DOI: 10.1200/JCO.2016.66.4482. View

Allen P, Lu X, Chen Q, OShea K, Chmiel J, Slonim L . Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma. Blood Adv. 2022; 7(12):2670-2676. PMC: 10333742. DOI: 10.1182/bloodadvances.2022008116. View

Ding W, LaPlant B, Call T, Parikh S, Leis J, He R . Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood. 2017; 129(26):3419-3427. PMC: 5492091. DOI: 10.1182/blood-2017-02-765685. View

10.

Ramsay A, Clear A, Fatah R, Gribben J . Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood. 2012; 120(7):1412-21. PMC: 3423779. DOI: 10.1182/blood-2012-02-411678. View

11.

Riches J, Davies J, McClanahan F, Fatah R, Iqbal S, Agrawal S . T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood. 2012; 121(9):1612-21. PMC: 3587324. DOI: 10.1182/blood-2012-09-457531. View

12.

Myklebust J, Irish J, Brody J, Czerwinski D, Houot R, Kohrt H . High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. Blood. 2013; 121(8):1367-76. PMC: 3578953. DOI: 10.1182/blood-2012-04-421826. View

13.

Mei M, Lee H, Palmer J, Chen R, Tsai N, Chen L . Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE. Blood. 2022; 139(25):3605-3616. PMC: 9227101. DOI: 10.1182/blood.2022015423. View

14.

Younes A, Santoro A, Shipp M, Zinzani P, Timmerman J, Ansell S . Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016; 17(9):1283-94. PMC: 5541855. DOI: 10.1016/S1470-2045(16)30167-X. View

15.

Carreras J, Lopez-Guillermo A, Roncador G, Villamor N, Colomo L, Martinez A . High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J Clin Oncol. 2009; 27(9):1470-6. DOI: 10.1200/JCO.2008.18.0513. View

16.

Carey C, Gusenleitner D, Lipschitz M, Roemer M, Stack E, Gjini E . Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. Blood. 2017; 130(22):2420-2430. PMC: 5766840. DOI: 10.1182/blood-2017-03-770719. View

17.

Steidl C, Gascoyne R . The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood. 2011; 118(10):2659-69. DOI: 10.1182/blood-2011-05-326538. View

18.

Menter T, Bodmer-Haecki A, Dirnhofer S, Tzankov A . Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas. Hum Pathol. 2016; 54:17-24. DOI: 10.1016/j.humpath.2016.03.005. View

19.

Advani R, Moskowitz A, Bartlett N, Vose J, Ramchandren R, Feldman T . Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. Blood. 2021; 138(6):427-438. DOI: 10.1182/blood.2020009178. View

20.

Smith S, Till B, Shadman M, Lynch R, Cowan A, Wu Q . Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapy. Br J Haematol. 2020; 189(6):1119-1126. DOI: 10.1111/bjh.16494. View